Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Fabhalta®
( iptacopan ) -
Extavia®
( interferon beta-1b )Neuroscience -
Exjade®
( deferasirox )Oncology -
Exforge®
( valsartan, amlodipine besylate )Cardiovascular, Renal and Metabolism -
Exforge HCT®
( valsartan, amlodipine besylate, hydrochlorothiazide )Cardiovascular, Renal and Metabolism -
Exelon®
( rivastigmine )Neuroscience -
Eucreas®
( vildagliptin, metformin )Cardiovascular, Renal and Metabolism -
Entresto®
( sacubitril, valsartan )Cardiovascular, Renal and Metabolism -
Egaten®
( triclabendazole )HepatologyAvailable in -
Durezol®
( difluprednate )OphthalmologyAvailable in